Back
Karyopharm Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
KPTI
Sponsored
Election Shock on August 19th?
Click here now to see the evidence I've gathered.
Sell
28
KPTI
Karyopharm Therapeutics
Last Price:
1.09
Seasonality Move:
-2.24%
7 Day Trial
ALL ACCESS PASS
$
7
Stock Market Legend Shares Biggest Prediction Ever:
Click Here to SeeKaryopharm Therapeutics Price Quote
$1.09
+0.06 (+5.83%)
(Updated: May 1, 2024 at 6:55 PM ET)
Karyopharm Therapeutics Key Stats
Sell
28
Karyopharm Therapeutics (KPTI)
is a Sell
Day range:
$1.02 - $1.14
52-week range:
$0.62 - $3.86
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.81
P/B ratio:
0%
Volume:
1.1M
Avg. volume:
1.1M
1-year change:
-71.23%
Market cap:
$118.5M
Revenue:
$146M
EPS:
$-1.25
How Much Does Karyopharm Therapeutics Make?
-
How Much Are Karyopharm Therapeutics's Sales Annually?
KPTI Revenues are $146M -
How Much Profit Does Karyopharm Therapeutics's Make A Year?
KPTI net income is -$143.1M
Is Karyopharm Therapeutics Growing As A Company?
-
What Is Karyopharm Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0% -
What Is Karyopharm Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Karyopharm Therapeutics Stock Price Performance
-
Did Karyopharm Therapeutics Stock Go Up Last Month?
Karyopharm Therapeutics share price went down by -31.79% last month -
Did KPTI's Share Price Rise Over The Last Year?
KPTI share price fell by -71.23% over the past 1 year
What Is Karyopharm Therapeutics 52-Week High & Low?
-
What Is Karyopharm Therapeutics’s 52-Week High Share Price?
Karyopharm Therapeutics has traded as high as $3.86 over the past 52 weeks -
What Is Karyopharm Therapeutics’s 52-Week Low Share Price?
Karyopharm Therapeutics has traded as low as $0.62 over the past 52 weeks
Karyopharm Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Karyopharm Therapeutics?
-
How Much Debt Does Karyopharm Therapeutics Have?
Total long term debt quarterly is $170.9M -
How Much Cash Does Karyopharm Therapeutics Have?
Cash and short term investments quarterly total is $191.4M -
What Is Karyopharm Therapeutics’s Book Value Per Share?
Book value per share is -1.19
Is Karyopharm Therapeutics Cash Flow Positive?
-
What Is KPTI Cash Flow From Operations?
Cash flow from operations (TTM) is -$92.7M -
What Is Karyopharm Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $1.1M -
What Is Karyopharm Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $7.9M
Karyopharm Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
KPTI return on invested capital is -148.18% -
What Is Karyopharm Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -47.95% -
What Is KPTI Return On Equity?
ROE is a measure of profitability and is 0%
Karyopharm Therapeutics Earnings Date & Stock Price
-
What Is Karyopharm Therapeutics's Stock Price Today?
A single share of KPTI can be purchased today for 1.03 -
What Is Karyopharm Therapeutics’s Stock Symbol?
Karyopharm Therapeutics trades on the nasdaq under the ticker symbol: KPTI -
When Is Karyopharm Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Karyopharm Therapeutics is scheduled on May 3, 2024 -
When Is KPTI's next ex-dividend date?
Karyopharm Therapeutics's next ex-dividend date is May 2, 2024 -
How To Buy Karyopharm Therapeutics Stock?
You can buy Karyopharm Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Karyopharm Therapeutics Competitors
-
Who Are Karyopharm Therapeutics's Competitors?
Below is a list of companies who compete with Karyopharm Therapeutics or are related in some way:
Karyopharm Therapeutics Dividend Yield
Data Unavailable
Karyopharm Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -16.24% |
Revenue: | 0.5% | 0.39% |
Analyst Recommendations
Buy Recommendations: | 2 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 5.57 |
Upside from Last Price: | 440.92% |